Table 1.

Clinical profiles of patients affected by colon adenocarcinoma and corresponding immunohistochemical expression of transforming growth factor β1 receptor type I (TGF-β1-RI) and type II (TGF-β-RII)

					TGF-β1-RI*		TGF-β1-RII*
Patient	Sex	Age (y)	pTNM	Histology (grading)	N	Ca	N	Ca
BB	F	46	T3N2M1	G2	54	100	100	100
CV	M	50	T3N0M0	G2	97	78	93	100
DP	F	46	T2N0M0	G2	88	59	99	100
MA	M	68	T3N0M0	G2	100	98	100	100
PR	F	61	T3N2Mx	G2	51	66	82	100
TE	M	80	T2N0M0	G2	10	30	8	9
BM	M	59	T3N0M0	G2	72	100	100	100
CA	M	56	T2N0M0	G2	100	100	100	90
DG	F	56	T2N0M0	G2	100	14	100	100
PI	F	72	T2NxM0	G2	100	58	88	50
CP	M	69	T3N1Mx	G2	94	6	100	97
CG	M	59	T3N0M0	G3	90	100	100	100
MB	M	90	T3N0M0	G3	100	6	100	100
GS	F	54	T4N2M1	G3	100	100	100	67
TZ	F	72	T4N1M0	G3	100	2	100	50

N, normal colorectal tissue; Ca, cancerous tissue.

pTNM classification: pT, extent of the primary tumour (T2, tumour invading muscularis propria; T3, tumour invading subserosa; T4, tumour directly invading other organs and/or visceral peritoneum); pN, regional lymph node metastasis (Nx, local lymph nodes not evaluable; N0, local lymph nodes without metastasis; N1, metastasis in 1–3 local lymph nodes; N2, metastasis in four or more local lymph nodes); pM, distant metastases (Mx, metastases not evaluable; M0, no metastasis; M1, presence of metastases).

Histological tumour deviation was graded as follows: G2, moderate; G3, intense.

*The number of positive TGF-β1-RI and TGF-β1-RII cells are expressed as a percentage of the total cells examined at 250× magnification (for each slide, 20 non-consecutive randomised histological fields were evaluated).